Co-Authors
This is a "connection" page, showing publications co-authored by Dezheng Huo and Katharine Yao.
Connection Strength
2.840
-
Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes. J Surg Oncol. 2015 Dec; 112(8):809-14.
Score: 0.468
-
Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1-T2 and One to Three Positive Lymph Nodes. Ann Surg Oncol. 2015 Dec; 22(13):4295-304.
Score: 0.450
-
Utilization of accelerated partial breast irradiation for ductal carcinoma in situ, 2003-2011: report from the national cancer database. Ann Surg Oncol. 2014 Oct; 21(11):3457-65.
Score: 0.423
-
Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. Breast Cancer Res Treat. 2013 Dec; 142(3):465-76.
Score: 0.409
-
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer. medRxiv. 2026 May 05.
Score: 0.243
-
Declination of Treatment, Racial and Ethnic Disparity, and Overall Survival in US Patients With Breast Cancer. JAMA Netw Open. 2024 05 01; 7(5):e249449.
Score: 0.211
-
Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
Score: 0.132
-
Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat. 2017 04; 162(2):317-328.
Score: 0.128
-
Axillary surgery among estrogen receptor positive women 70 years of age or older with clinical stage I breast cancer, 2004-2010: a report from the National Cancer Data Base. Ann Surg Oncol. 2013 Oct; 20(10):3259-65.
Score: 0.101
-
Accelerated partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer patients undergoing breast conservation, 2003-2010: a report from the national cancer data base. Ann Surg Oncol. 2013 Oct; 20(10):3223-32.
Score: 0.101
-
Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings. JCO Glob Oncol. 2026 May; 12(5):e2500705.
Score: 0.061
-
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence. medRxiv. 2026 May 12.
Score: 0.061
-
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence. NPJ Breast Cancer. 2024 Jun 15; 10(1):46.
Score: 0.053